Skip to main content
Log in

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

  • Short communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary.

Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year.

The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total-and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P < 0.05). No serious adverse effects were observed.

The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hermann LS, Melander A (1990) Biguanides: Basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmel P (eds). The international textbook of diabetes mellitus. John Wiley and Sons, Baltimore

    Google Scholar 

  2. Betteridge DJ (1989) Lipids, diabetes and vascular disease: The time to act. Diabetic Med 61: 195–218

    Google Scholar 

  3. Gerich JE (1989) Oral hypoglycaemic agents. N Engl J Med 321: 1231–1245

    Google Scholar 

  4. Taylor KG, John WG, Matthews KA, Wright AD (1982) A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-1 and B in type 2 (non-insulin-dependent) diabetes. Diabetologia 23: 507–510

    Google Scholar 

  5. Rains SGH, Wilson GA, Richmond W, Elkeles RS (1988) The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 5: 653–658

    Google Scholar 

  6. Vague PH, Juhan-Vague I, Alessi MC, Badier C, Valadier J (1987) Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57: 326–328

    Google Scholar 

  7. Wu M-S, Johnston P, Sheu WH-H, Hollenbeck CB, Jeng C-Y, Goldfine ID, Chen Y-DI, Reaven GM (1990) Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13: 1–8

    Google Scholar 

  8. Rains SGH, Wilson GA, Richmond W, Elkeles RS (1989) The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J Royal Soc Med 82: 93–94

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hermann, L.S., Karlsson, J.E. & Sjöstrand, Å. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 41, 263–265 (1991). https://doi.org/10.1007/BF00315441

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315441

Key words

Navigation